IPIC Message Board - Msg: 1934821

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

+899.9%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (520)	8/8/1997 5:54:00 PM
From: Biomaven	of 1359

Andrew, I think the above comments are based on a hasty reading of the trial results. The issue was not whether "they knew their indication" - it was that by chance a very large number of the mild stroke patients were assigned to the placebo. These mild stroke patients mostly recovered with or without the drug. On the other hand the moderate and severe stroke patients had a very solid response to the drug (41% vs. 25% p=.02). This coupled with no adverse effects makes the drug, in my opinion, highly likely to pass FDA muster. No results on ischemic damage size were released to my knowledge - they say these studies are continuing. Remember the FDA approved TPA for stroke, despite the not-inconsiderable risk of fatal bleeding. Citicoline has minimal side-effects and clear evidence of effectiveness in at least some people. Peter Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next